PLoS ONE (Jan 2022)

Proteomic profiling of serum identifies a molecular signature that correlates with clinical outcomes in COPD.

  • Rania Dagher,
  • Paul Fogel,
  • Jingya Wang,
  • David Soussan,
  • Chia-Chien Chiang,
  • Jennifer Kearley,
  • Daniel Muthas,
  • Camille Taillé,
  • Patrick Berger,
  • Arnaud Bourdin,
  • Cécile Chenivesse,
  • Sylvie Leroy,
  • Gary Anderson,
  • Alison A Humbles,
  • Michel Aubier,
  • Roland Kolbeck,
  • Marina Pretolani,
  • COBRA Consortium

DOI
https://doi.org/10.1371/journal.pone.0277357
Journal volume & issue
Vol. 17, no. 12
p. e0277357

Abstract

Read online

ObjectiveNovel biomarkers related to main clinical hallmarks of Chronic obstructive pulmonary disease (COPD), a heterogeneous disorder with pulmonary and extra-pulmonary manifestations, were investigated by profiling the serum levels of 1305 proteins using Slow Off-rate Modified Aptamers (SOMA)scan technology.MethodsSerum samples were collected from 241 COPD subjects in the multicenter French Cohort of Bronchial obstruction and Asthma to measure the expression of 1305 proteins using SOMAscan proteomic platform. Clustering of the proteomics was applied to identify disease subtypes and their functional annotation and association with key clinical parameters were examined. Cluster findings were revalidated during a follow-up visit, and compared to those obtained in a group of 47 COPD patients included in the Melbourne Longitudinal COPD Cohort.ResultsUnsupervised clustering identified two clusters within COPD subjects at inclusion. Cluster 1 showed elevated levels of factors contributing to tissue injury, whereas Cluster 2 had higher expression of proteins associated with enhanced immunity and host defense, cell fate, remodeling and repair and altered metabolism/mitochondrial functions. Patients in Cluster 2 had a lower incidence of exacerbations, unscheduled medical visits and prevalence of emphysema and diabetes. These protein expression patterns were conserved during a follow-up second visit, and substanciated, by a large part, in a limited series of COPD patients. Further analyses identified a signature of 15 proteins that accurately differentiated the two COPD clusters at the 2 visits.ConclusionsThis study provides insights into COPD heterogeneity and suggests that overexpression of factors involved in lung immunity/host defense, cell fate/repair/ remodelling and mitochondrial/metabolic activities contribute to better clinical outcomes. Hence, high throughput proteomic assay offers a powerful tool for identifying COPD endotypes and facilitating targeted therapies.